Studies published in 2012 in the field of HDL research have provided further evidence suggesting that a low HDL-cholesterol level, in the absence of related lipid or nonlipid risk factors, is not associated with increased risk of coronary heart disease.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Association between High-density-lipoprotein-cholesterol Levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis
Scientific Reports Open Access 03 April 2017
-
The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status – a cohort study
Nutrition & Metabolism Open Access 01 October 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Després, J. P., Lemieux, I., Dagenais, G. R., Cantin, B. & Lamarche, B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 153, 263–272 (2000).
Brewer, H. B. Jr. Clinical review: The evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. J. Clin. Endocrinol. Metab. 96, 1246–1257 (2011).
Barter, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755–1766 (2012).
Nissen, S. E. et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N. Engl. J. Med. 356, 1304–1316 (2007).
Barter, P. J. et al. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109–2122 (2007).
Schwartz, G. G. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367, 2089–2099 (2012).
Voight, B. F. et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 380, 572–580 (2012).
Mackey, R. H. et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J. Am. Coll. Cardiol. 60, 508–516 (2012).
Parish, S. et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 125, 2469–2478 (2012).
Arsenault, B. J. & Després, J. P. Lipids: HDL cholesterol is not HDL—don't judge the book by its cover. Nat. Rev. Cardiol. 9, 557–558 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J.-P. Després has received honoraria from Abbott, AstraZeneca, GlaxoSmithKline, Merck, and Pfizer Canada, and has acted as a consultant for Novartis, Sanofi, Theratechnologies, and Torrent Pharmaceuticals.
Rights and permissions
About this article
Cite this article
Després, JP. HDL cholesterol studies—more of the same?. Nat Rev Cardiol 10, 70–72 (2013). https://doi.org/10.1038/nrcardio.2012.182
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2012.182
This article is cited by
-
Association between High-density-lipoprotein-cholesterol Levels and the Prevalence of Asymptomatic Intracranial Arterial Stenosis
Scientific Reports (2017)
-
The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status – a cohort study
Nutrition & Metabolism (2013)
